Learn / Clinical Research Management / Foundations: ethics, GCP and the drug development pathway
The drug development pathway and trial phases
14 minute read · 6-question quiz
What you will learn
Describe the stages from discovery to post-marketing surveillance
Distinguish phase I, II, III and IV trials by purpose, size and population
Explain the roles of non-clinical studies, regulatory submission and post-approval evidence
Developing a new medicine typically takes ten years or more and costs a very large sum, and most candidates fail. The pathway is staged so that safety is demonstrated before exposure widens.
Before humans
- Discovery and non-clinical studies: laboratory and animal work to study pharmacology, toxicology, and safe starting doses.
- Manufacturing to GMP standards, with quality control.
- Regulatory and ethics approval to start the first human study (an Investigational New Drug or Clinical Trial Application).
Clinical phases
- Phase I: first in humans, usually 20 to 100 healthy volunteers (or patients for toxic drugs such as cancer therapies). Questions: Is it safe? How is it absorbed, distributed and eliminated? What dose is tolerated?
- Phase II: a few hundred patients with the disease. Questions: Does it show signs of working? What dose and schedule? What are common side effects? Often divided into IIa (proof of concept) and IIb (dose-finding).
- Phase III: confirmatory trials in hundreds to thousands of patients, usually randomised and controlled. Questions: Is it effective and safe compared with the standard of care or placebo? These trials form the main basis for marketing approval.
- Regulatory review and approval: the sponsor submits the full dossier (the common technical document). Regulators assess quality, safety and efficacy and decide whether to authorise.
- Phase IV (post-marketing): studies after approval to find rare or long-term adverse events and effects in wider populations, plus ongoing pharmacovigilance.
Attrition
Many candidates drop out at each stage because of toxicity, lack of efficacy or commercial reasons. Only a small fraction of medicines entering human trials reach approval, so each phase acts as a filter that spares later participants and patients from ineffective or unsafe products.
Other kinds of trial
- Bioequivalence studies for generics, comparing absorption with the reference product.
- Vaccine trials, with immunogenicity and efficacy endpoints.
- Device and diagnostic studies with their own regulatory pathways.
- Pragmatic and real-world studies that test effectiveness in routine care.
Summary
Medicines move through non-clinical work, phases I to III, regulatory approval and phase IV surveillance.
Phase I tests safety and dose, phase II looks for efficacy signals, phase III confirms benefit.
Phase IV and pharmacovigilance detect rare and long-term harms after approval.
Classification follows purpose; Africa-based trials add relevant evidence and capacity.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.